Based on the down-regulation of MAP2K6 in sh-APEX1-treated HCC cells and a positive expression correlation between APEX1 and MAP2K6 in HCC tissues (Figure 6A), we predicted that APEX1 enhances the malignant properties of HCC via its impact on MAP2K6 expression. The gene discussed is APEX1; the disease is hepatocellular carcinoma.